Original Article

Reducing catheter urinary tract infection risk through biofilm prevention: evidence-based strategies for urinary catheter management

Abstract

Background and Objectives: Catheter-associated urinary tract infections (CAUTIs) are common healthcare-associated infections mainly caused by biofilm formation on urinary catheters. This study aimed to provide evidence-based catheter management strategies to reduce CAUTI risk through biofilm prevention.
Materials and Methods: This prospective observational study included 109 adult patients undergoing urinary catheterization between September 2017 and January 2018. Urine samples were collected after catheter insertion and before catheter removal. Bacteriuria was screened using flow cytometry and confirmed by urine culture. Removed catheters were cultured to assess biofilm formation, while isolates were tested for biofilm-forming ability using Congo Red Agar (CRA).
Results: The mean catheterization duration was 5.6 ± 2.1 days, and most patients were catheterized for ≥5 days. Bacteriuria was significantly associated with catheterization (p = 0.029). Antibiotic use reduced bacteriuria incidence (p < 0.001) but did not significantly reduce biofilm formation (73.4%, p > 0.05). CRA-positive isolates showed 1.5-fold greater biofilm-forming potential. Female sex, early bacteriuria, and catheterization >5 days were associated with biofilm formation.
Conclusion: Urinary catheterization promotes biofilm and increases CAUTI risk. Although antibiotics reduced bacteriuria, they showed limited efficacy against biofilms. Early bacteriuria screening, routine monitoring, biofilm prevention, and limiting catheter duration may help reduce CAUTI incidence.

1. Werneburg GT. Catheter-associated urinary tract infections: Current challenges and future prospects. Res Rep Urol 2022;14: 109-133.
2. Centers for Disease Control and Prevention. Catheter-associated Urinary Tract Infection (CAUTI) Basics [Internet]. [cited 2026 Jan 10]. Available from: https://www.cdc.gov/uti/about/cauti-basics.html
3. Sleziak J, Błażejewska M, Duszyńska W. Catheter-associated urinary tract infections in the intensive care unit during and after the COVID-19 pandemic. BMC Infect Dis 2025; 25: 595.
4. Gunardi WD, Karuniawati A, Umbas R, Bardosono S, Lydia A, Soebandrio A, et al. Biofilm-Producing Bacteria and Risk Factors (Gender and Duration of Catheterization) Characterized as Catheter-Associated Biofilm Formation. Int J Microbiol 2021; 2021: 8869275.
5. Tegegne DT, Abbott IJ, Poźniak B. Catheter-Associated Urinary Tract Infections: Understanding the Interplay Between Bacterial Biofilm and Antimicrobial Resistance. Int J Mol Sci 2025; 26: 9193.
6. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control 2004; 32: 177-183.
7. Gunardi WD, Timotius KH, Natasha A, Evriarti PR. Biofilm Targeting Strategy in the Eradication of Burkholderia Infections: A Mini-Review. Open Microbiol J 2021; 15: 51-57.
8. Wang G, Wang X, Sun L, Gao Y, Niu X, Wang H. Novel Inhibitor Discovery of Staphylococcus aureus Sortase B and the Mechanism Confirmation via Molecular Modeling. Molecules 2018; 23: 977.
9. Karygianni L, Ren Z, Koo H, Thurnheer T. Biofilm Matrixome: Extracellular Components in Structured Microbial Communities. Trends Microbiol 2020; 28: 668-681.
10. Sahoo K, Meshram S. Biofilm Formation in Chronic Infections: A Comprehensive Review of Pathogenesis, Clinical Implications, and Novel Therapeutic Approaches. Cureus 2024; 16(10): e70629.
11. Mendhe S, Badge A, Ugemuge S, Chandi D. Impact of Biofilms on Chronic Infections and Medical Challenges. Cureus 2023; 15(11): e48204.
12. Gunardi WD, Dharmawan A, Layanto N. Antibiotic effectiveness on biofilm-producing Escherichia coli isolated from catheterized patients. J Med Sci (Berkala Ilmu Kedokteran) 2022; 54: 211-221.
13. Letica-Kriegel AS, Salmasian H, Vawdrey DK, Youngerman BE, Green RA, Furuya EY, et al. Identifying the risk factors for catheter-associated urinary tract infections: a large cross-sectional study of six hospitals. BMJ Open 2019; 9(2): e022137.
14. Perdana MA, Wahyuni DD, Yunita R. Characteristics and susceptibility pattern of catheter-associated urinary tract infections (CAUTI) bacteria in Indonesia: A study in a national reference hospital of Sumatra region 2020–2021. Narra J 2023; 3(3): e436.
15. Ghali H, Saad OKB, Bhiri S, Balhi S, Azouzi F, Maatouk A, et al. Epidemiology and risk factors of healthcare-associated urinary tract infections: a prospective study in a Tunisian tertiary hospital. Sci Rep 2025; 15: 29948.
16. Skok K, Bele U, Pintar Š, Peršin Z, Kuzmič K, Bračič M, et al. Urinary catheters: state of the art and future perspectives - a narrative review. Mater Today Bio 2025; 34: 102225.
17. Rubi H, Mudey G, Kunjalwar R. Catheter-Associated Urinary Tract Infection (CAUTI). Cureus 2022; 14(10): e30385.
18. Chakraverty R, Kundu AK (2024). Catheter-Associated Urinary Tract Infections (CAUTI): Prevalence and Management. In: Hospital-Acquired Infections in Intensive Care Unit and Their Management. Singapore: Springer Nature Singapore, pp. 55-66.
19. Sivanandy P, Manirajan P, Wen Qi O, Teng Khai O, Chun Wei O, Wei Ying N, et al. A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections. Ann Med 2024; 56: 2403724.
20. Martins KB, Ferreira AM, Pereira VC, Pinheiro L, de Oliveira A, da Cunha MLRS. In vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus saprophyticus Isolated From Patients With Urinary Tract Infections. Front Microbiol 2019; 10: 40.
21. Abebe GM. The role of bacterial biofilm in antibiotic resistance and food contamination. Int J Microbiol 2020; 2020: 1705814.
22. Sharif S, Yadav AK. Bacterial biofilm and its role in antibiotic resistance. The Microbe 2025; 7: 100356.
23. Li N, Shi R, Sun Y, Chen Q. Effective interventions to prevent catheter-associated urinary tract infections: a systematic review. Rev Inst Med Trop Sao Paulo 2025; 67: e61.
24. Van Der Zwet WC, Hessels J, Canbolat F, Deckers MM. Evaluation of the Sysmex UF-1000i® urine flow cytometer in the diagnostic work-up of suspected urinary tract infection in a Dutch general hospital. Clin Chem Lab Med 2010; 48: 1765-1771.
25. Le Z, Li F, Fei C, Ye A, Xie X, Zhang J. Performance of the Sysmex UF-1000i urine analyser in the rapid diagnosis of urinary tract infections in hospitalized patients. J Infect Chemother 2016; 22: 377-382.
26. Fernández-Calderón MC, Fernández-Babiano I, Navarro-Pérez ML, Pazos-Pacheco C, Calvo-Cano A. Biofilm formation and role of other pathogenic factors in the virulence of Staphylococcus epidermidis clinical isolates. Front Cell Infect Microbiol 2025; 15: 1630341.
27. Martínez-García S, Ortega-Peña S, De Haro-Cruz MJ, Aguilera-Arreola MG, Alcántar-Curiel MD, Betanzos-Cabrera G, et al. Non-biofilm-forming commensal Staphylococcus epidermidis isolates produce biofilm in the presence of trypsin. Microbiologyopen 2019; 8(10): e906.
28. Wang J, Zhang Y, Xu D, Shao W, Lu Y. Evaluation of the Sysmex UF-1000i for the diagnosis of urinary tract infection. Am J Clin Pathol 2010; 133: 577-582.
Files
IssueVol 18 No 4 (2026) QRcode
SectionOriginal Article(s)
Keywords
Anti-bacterial agents Biofilms Bacteriuria Treatment Urinary tract infections
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Gunardi W, Dharmawan A, Herawan Timotius K. Reducing catheter urinary tract infection risk through biofilm prevention: evidence-based strategies for urinary catheter management. Iran J Microbiol. 2026;18(4):482-489.